查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1643910

全球組織工程市場 - 2025-2033

Global Tissue Engineering Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球組織工程市場在2024年達到189億美元，預計2033年將達到651億美元，2025-2033年預測期間複合年成長率為14.9%。

組織工程是了解某些疾病如何進展以及如何治療的重要工具。它是生物工程領域的一部分，生物工程是一門結合了生物學和工程學原理的廣泛學科。生物工程有時被描述為採用工程方法來研究生物學。組織工程涉及研究組織發育、損傷和傷口癒合中涉及的生物、物理和化學力。

組織工程的目標是製造能夠與患者身體無縫整合的功能性組織和器官，最終改善患者的治療結果和生活品質。該領域涵蓋各種方法，包括基於支架的技術、基於細胞的療法和生物活性分子遞送系統。

隨著組織工程領域的進步和組織工程資金的增加，組織工程市場正在經歷持續成長。例如，2023 年 11 月，SPRIND Funke Tissue Engineering 與四個雄心勃勃的團隊啟動了為期十個月的旅程，探索和展示人造組織的關鍵特性。 SPRIND 提供了高達 50 萬歐元的資金來支持這項開創性的工作。

市場動態：

驅動程式和限制

慢性病盛行率上升

慢性病盛行率的上升極大地推動了組織工程市場的成長，預計將在預測期內推動該市場的成長。隨著糖尿病、心血管疾病、骨關節炎和腎臟疾病等慢性疾病在全球的增加，對包括組織工程在內的先進治療方案的需求也在增加。

例如，根據世界衛生組織統計，每年估計有 1790 萬人死於心血管疾病 (CVD)，使其成為世界上最主要的死亡原因。全球 4.22 億糖尿病患者中的大部分居住在低收入和中等收入國家，該疾病每年直接導致 150 萬人死亡。全球約有 17.1 億人患有肌肉骨骼疾病。由於多種慢性疾病發生率的上升，預計對組織工程的需求將會增加。

慢性疾病通常會導致傳統治療無法完全修復的組織損傷或退化。組織工程透過創造替代組織或器官來提供解決方案，幫助癒合和再生。例如，糖尿病患者的傷口癒合不良，需要組織工程來修復皮膚或血管。

此外，腦、肺、肝臟和骨組織工程的發展有助於創建癌症轉移的體外模型。由於組織工程提供了直接檢查癌症發生和轉移灶遷移的方法，因此它有可能徹底改變癌症研究。由於誘導血管生成是癌症的關鍵特徵，因此新血管形成通常與實體腫瘤的形成有關。此外，組織工程使得複製腫瘤微環境及其所有複雜和多方面的特徵成為可能。因此，癌症病例的增加增加了對組織工程的需求。

與組織工程技術相關的高成本

與組織工程技術相關的高成本是阻礙組織工程市場成長的主要因素之一。雖然組織工程有望解決慢性疾病和組織損傷，但其開發、生產和實施所涉及的成本是巨大的。例如，根據美國國立衛生研究院 (NIH) 的數據，三名英國患者接受幹細胞組織工程氣道移植的總費用為 174,420 美元至 740,500 美元。

由於需要專門的生物列印機、先進的生物材料和熟練的技術人員，使用 3D 列印技術開發生物列印組織的成本非常高。儘管該技術具有巨大的潛力，但目前尚無法廣泛使用。例如，據 ResearchGate 稱，生物列印技術的價格從 5,000 美元到超過 50 萬美元不等。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按材料類型分類的片段
  • 技術片段
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 慢性病盛行率上升
    • 限制
      • 與組織工程技術相關的高成本
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：組織工程市場（依材料類型）

  • 合成材料
    • 聚合物
    • 水凝膠
    • 陶瓷
    • 複合材料
  • 天然材質
    • 細胞外基質 (ECM) 蛋白
    • 纖維蛋白
    • 膠原
    • 絲綢
  • 奈米纖維支架
  • 蛋白質基材料
  • 其他

第 6 章：依技術分類的組織工程市場

  • 生物材料和支架
  • 細胞培養
  • 生物反應器和培養系統
  • 生物列印
  • 其他

第 7 章：組織工程市場（按應用）

  • 肌肉骨骼
  • 皮膚和外皮
  • 心臟病學
  • 神經病學
  • 其他

第 8 章：組織工程市場（依最終使用者）

  • 醫院和診所
  • 合約開發和製造組織
  • 研究和學術機構
  • 生物技術和製藥公司

第 9 章：組織工程市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 11 章：公司簡介

  • 3D BioFibR Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • CollPlant Biotechnologies Ltd.
  • Lonza Group
  • InSphero AG
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Corning Incorporated
  • Prellis Biologics
  • Collagen Solutions (US) LLC
  • SunP BIOTECH
  • Cellink

第 12 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 13 章：附錄

簡介目錄
Product Code: BT6742

The global tissue engineering market reached US$ 18.9 billion in 2024 and is expected to reach US$ 65.1 billion by 2033, growing at a CAGR of 14.9% during the forecast period 2025-2033.

Tissue engineering is an important tool in understanding how certain conditions progress and how they can be treated. It is part of the field of bioengineering, a broad discipline that combines principles from biology and engineering. Bioengineering is sometimes described as taking an engineering approach to the study of biology. Tissue engineering involves investigating the biological, physical, and chemical forces involved in tissue development, injury, and wound healing.

The goal of tissue engineering is to fabricate functional tissues and organs that can integrate seamlessly with the patient's body, ultimately improving patient outcomes and quality of life. This field encompasses various approaches, including scaffold-based techniques, cell-based therapies and bioactive molecule delivery systems.

The tissue engineering market is experiencing consistent growth with advancements in the field of tissue engineering and rising funding for tissue engineering. For instance, in November 2023, SPRIND Funke Tissue Engineering launched a ten-month journey to explore and demonstrate the key characteristics of artificial tissue embarking with four ambitious teams. SPRIND provided up to EUR 500,000 in funding to support this groundbreaking work.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the tissue engineering market and is expected to drive the market over the forecast period. As chronic diseases such as diabetes, cardiovascular diseases, osteoarthritis and kidney disorders increase globally, the need for advanced treatment options, including tissue engineering, has grown.

For instance, according to the WHO, an estimated 17.9 million people die from cardiovascular diseases (CVDs) each year, making them the world's leading cause of mortality. The bulk of the 422 million individuals with diabetes globally reside in low- and middle-income nations, and the disease is directly responsible for 1.5 million fatalities annually. Around 1.71 billion people worldwide suffer from musculoskeletal disorders. The need for tissue engineering is expected to rise as a result of the rising incidence of numerous chronic illnesses.

Chronic diseases often lead to tissue damage or degeneration that traditional treatments cannot fully repair. Tissue engineering offers solutions by creating replacement tissues or organs, aiding in healing and regeneration. For instance, diabetic patients suffer from poor wound healing, necessitating tissue engineering for skin or vascular repair.

Additionally, developments in brain, lung, liver, and bone tissue engineering are useful for creating in vitro models of cancer metastasis. Because tissue engineering offers ways to directly examine carcinogenesis and migration at metastases, it has the potential to revolutionize cancer research. Since inducing angiogenesis is a key characteristic of cancer, neovascularization is frequently linked to the formation of solid tumors. Additionally, tissue engineering makes it possible to replicate the tumor microenvironment and all of its intricate and multifaceted features. Thus, rising cancer cases boosts the demand for tissue engineering.

High cost associated with the tissue engineering technique

The high cost associated with tissue engineering techniques is one of the major factors hampering the growth of the tissue engineering market. While tissue engineering holds promise for addressing chronic diseases and tissue damage, the costs involved in its development, production, and implementation are significant. For instance, according to the National Institute of Health (NIH), the total costs of stem cell-based tissue-engineered airway transplants for the three UK patients treated ranged from $174,420 to $740,500.

The development of bioprinted tissues using 3D printing technology is highly cost-intensive due to the need for specialized bioprinting machines, advanced biomaterials, and skilled technicians. While it holds significant potential, this technology is not yet affordable for widespread use. For instance, according to ResearchGate, bioprinting techniques prices range from $5,000 to over $500,000.

Segment Analysis

The global tissue engineering market is segmented based on material type, technology, application, end-user and region.

Technology:

The biomaterials and scaffolds segment is expected to dominate the tissue engineering market share

Biomaterials and scaffolds serve as the foundation for tissue regeneration by providing structural support for growing cells and promoting tissue formation. Biomaterials interact with biological systems to promote desired therapeutic outcomes, such as tissue regeneration, repair or replacement. In tissue engineering, biomaterials serve as scaffolds, carriers or matrices for cells and bioactive molecules, providing a supportive environment for tissue formation and integration. Thus, biomaterials and scaffolds are highly used for many research activities.

For instance, in November 2023, To conduct the research, Dr. ZHAO combined several disciplines, including material science, cell biology, engineering, and medicine. Her research focuses on modifying cell microenvironments, influencing cell behaviors, and promoting the growth of tissue-engineered organs. Her research team actively studies how cells perceive, interact, and evolve with biomaterials to restore diseased or damaged tissues to create patient-oriented biomaterials with distinctive shapes and properties.

Biomaterials serve as carriers for bioactive molecules, therapeutic agents or cells in tissue engineering applications. These biomaterials are used in bioprinting and pharmaceutical drug development. For instance, in September 2022, 3D Systems established Systemic Bio, a new, fully owned business. Systemic Bio will use biomaterials and human cells to produce incredibly accurate vascularized organ models by utilizing 3D Systems' innovative, production-level bioprinting technology. At the very beginning of the creation of new pharmaceutical drugs, these unique organs-on-chips can be produced in huge quantities with reproducible results and then perfused with any desired drug molecule to research drug metabolism and its effects on healthy or sick tissue.

Geographical Analysis

North America is expected to hold a significant position in the tissue engineering market share

North America is home to many leading companies in the tissue engineering space, which drive innovation and commercialization. These companies are involved in developing biomaterials, scaffolds, and cell-based therapies for various applications, including orthopedics, cardiovascular diseases, and wound healing.

Companies like Organovo, a leader in 3D bioprinting, Medtronic and other emerging players that develop advanced tissue engineering solutions, have strong presences in North America. The presence of these market leaders fosters a competitive environment that accelerates market growth.

For instance, in August 2024, CytoNest Inc. launched its first commercial product, a fiber scaffold that enhances tissue engineering and cell production. Applications for the product, known as CytoSurge 3D fiber scaffold, include cell research, biopharmaceutical cell therapies and the generation of cultured meat and seafood.

Asia-Pacific is growing at the fastest pace in the tissue engineering market

Tissue engineering in the Asia-Pacific region is expanding from research into clinical applications, with several companies and research institutions moving toward commercialization. The clinical application of tissue engineering technologies such as 3D bioprinting helps in treating conditions like skin burns, bone fractures, cartilage damage, organ failure and others are gaining momentum.

For instance, in November 2024, Scire Science, a biotech company based in Kochi, made history by introducing India's first patented domestic bioink for sophisticated 3D bioprinting applications. This invention positions Scire Science as an Indian leader in a field dominated by a small number of multinational corporations. With the use of sophisticated 3D bioprinting, this technique makes it possible to biofabricate the tissues of the liver, kidney, pancreas, skin, brain and heart.

Competitive Landscape

The major global players in the tissue engineering market include 3D BioFibR Inc., CollPlant Biotechnologies Ltd, Lonza Group, InSphero AG, Merck KGaA, Thermo Fisher Scientific Inc., Corning Incorporated, Prellis Biologics, Collagen Solutions (US) LLC, SunP BIOTECH, Cellink and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global tissue engineering market report delivers a detailed analysis with 73 key tables, more than 70 visually impactful figures, and 197 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost Associated with the Tissue Engineering Technique
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. SWOT Analysis
  • 4.9. Unmet Needs and Gaps
  • 4.10. Recommended Strategies for Market Entry and Expansion
  • 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.12. Pricing Analysis and Price Dynamics

5. Tissue Engineering Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Synthetic Materials*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Polymers
    • 5.2.4. Hydrogels
    • 5.2.5. Ceramics
    • 5.2.6. Composites
  • 5.3. Natural Materials
    • 5.3.1. Extracellular Matrix (ECM) Proteins
    • 5.3.2. Fibrin
    • 5.3.3. Collagen
    • 5.3.4. Silk
  • 5.4. Nanofiber Scaffolds
  • 5.5. Protein-Based Materials
  • 5.6. Others

6. Tissue Engineering Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Biomaterials and Scaffolds*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cell Culture
  • 6.4. Bioreactors and Culture Systems
  • 6.5. Bio-printing
  • 6.6. Others

7. Tissue Engineering Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Musculoskeletal*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Skin & Integumentary
  • 7.4. Cardiology
  • 7.5. Neurology
  • 7.6. Others

8. Tissue Engineering Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals and Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Contract Development and Manufacturing Organization
  • 8.4. Research and Academic Institutes
  • 8.5. Biotechnology and Pharmaceutical Companies

9. Tissue Engineering Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. 3D BioFibR Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. CollPlant Biotechnologies Ltd.
  • 11.3. Lonza Group
  • 11.4. InSphero AG
  • 11.5. Merck KGaA
  • 11.6. Thermo Fisher Scientific Inc.
  • 11.7. Corning Incorporated
  • 11.8. Prellis Biologics
  • 11.9. Collagen Solutions (US) LLC
  • 11.10. SunP BIOTECH
  • 11.11. Cellink

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us